
|Videos|January 23, 2023
Safety and Efficacy Data from CheckMate 274 on Adjuvant Nivolumab Therapy for Patients with MIBC
Author(s)Matthew Galsky, MD
Matthew Galsky, MD, explains safety and efficacy data from the CheckMate 274 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC, and highlights important data updates from recent conferences.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
4
Erdafitinib Demonstrates Manageable Toxicity, Early Efficacy in Glioma
5








































